Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock Rating Lowered by Roth Capital

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded by analysts at Roth Capital from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

Separately, StockNews.com started coverage on shares of Cyclacel Pharmaceuticals in a research note on Tuesday. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Price Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.87 on Wednesday. Cyclacel Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $10.12. The business’s fifty day moving average price is $1.05 and its two-hundred day moving average price is $1.57. The company has a market capitalization of $1.87 million, a P/E ratio of -0.05 and a beta of 0.51.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same quarter in the previous year, the company earned ($6.60) EPS. On average, research analysts expect that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 23.58% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.